Success Metrics

Active Trials
4(67%)

Phase Distribution

Ph early_phase_1
4
67%
Ph phase_1
1
17%
Ph not_applicable
1
17%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
4(66.7%)
Phase 1Safety & dosage
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Other(1)

Detailed Status

Recruiting4
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 14 (66.7%)
Phase 11 (16.7%)
N/A1 (16.7%)

Trials by Status

not_yet_recruiting117%
recruiting467%
unknown117%

Recent Activity

4 active trials
Showing 5 of 6
not_yet_recruitingphase_1

Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL

NCT07334574
recruitingearly_phase_1

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

NCT06496373
recruitingearly_phase_1

XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

NCT06980155
recruitingearly_phase_1

Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05916248
recruitingearly_phase_1

Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

NCT05916261
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07334574Phase 1

Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL

Not Yet Recruiting
NCT06496373Early Phase 1

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Recruiting
NCT06980155Early Phase 1

XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

Recruiting
NCT05916248Early Phase 1

Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
NCT05916261Early Phase 1

Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

Recruiting
NCT05359354Not Applicable

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors

Unknown

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6